JP2016536342A5 - - Google Patents

Info

Publication number

JP2016536342A5

JP2016536342A5 JP2016542839A JP2016542839A JP2016536342A5 JP 2016536342 A5 JP2016536342 A5 JP 2016536342A5 JP 2016542839 A JP2016542839 A JP 2016542839A JP 2016542839 A JP2016542839 A JP 2016542839A JP 2016536342 A5 JP2016536342 A5 JP 2016536342A5

Authority

JP

Japan

Prior art keywords

seq

light chain

heavy chain

variable

antigen

Prior art date

2014-09-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 230000027455 binding Effects 0.000 claims 47
• 239000012634 fragment Substances 0.000 claims 46
• 239000000427 antigen Substances 0.000 claims 44
• 102000036639 antigens Human genes 0.000 claims 44
• 108091007433 antigens Proteins 0.000 claims 44
• 125000003275 alpha amino acid group Chemical group 0.000 claims 26
• 238000006467 substitution reaction Methods 0.000 claims 17
• 235000001014 amino acid Nutrition 0.000 claims 13
• 239000000562 conjugate Substances 0.000 claims 9
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
• 102000001301 EGF receptor Human genes 0.000 claims 5
• 108060006698 EGF receptor Proteins 0.000 claims 5
• 239000003795 chemical substances by application Substances 0.000 claims 5
• 206010028980 Neoplasm Diseases 0.000 claims 4
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 4
• 108010093470 monomethyl auristatin E Proteins 0.000 claims 4
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 230000008685 targeting Effects 0.000 claims 4
• 108020004707 nucleic acids Proteins 0.000 claims 3
• 102000039446 nucleic acids Human genes 0.000 claims 3
• 150000007523 nucleic acids Chemical class 0.000 claims 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
• 235000013922 glutamic acid Nutrition 0.000 claims 2
• 239000004220 glutamic acid Substances 0.000 claims 2
• 239000002773 nucleotide Substances 0.000 claims 2
• 125000003729 nucleotide group Chemical group 0.000 claims 2
• JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
• 230000001225 therapeutic effect Effects 0.000 claims 2
• 239000013598 vector Substances 0.000 claims 2
• 108090000695 Cytokines Proteins 0.000 claims 1
• 102000004127 Cytokines Human genes 0.000 claims 1
• 206010027476 Metastases Diseases 0.000 claims 1
• 102220531209 Uncharacterized protein KIAA2012_F27R_mutation Human genes 0.000 claims 1
• 239000000654 additive Substances 0.000 claims 1
• 230000000996 additive effect Effects 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 108010044540 auristatin Proteins 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 229960005395 cetuximab Drugs 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
• 239000004615 ingredient Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000009401 metastasis Effects 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• FNGYBCWZUBEMNP-UHFFFAOYSA-N pyridin-2-ylsulfanyl propanoate Chemical compound CCC(=O)OSC1=CC=CC=N1 FNGYBCWZUBEMNP-UHFFFAOYSA-N 0.000 claims 1
• 102220042393 rs116605307 Human genes 0.000 claims 1
• 102200148733 rs116840794 Human genes 0.000 claims 1
• 102220217100 rs201097255 Human genes 0.000 claims 1
• 102220342298 rs777367316 Human genes 0.000 claims 1
• 150000003839 salts Chemical group 0.000 claims 1
• 150000003384 small molecules Chemical class 0.000 claims 1